Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Clinical evidence

ABX464-102

52 evidence topics · 10 sources

Objective
Location and study date
Region of enrollment in the posted results
CountryParticipants
Belgium“3”
Poland“10”
Hungary“9”
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Allocation“N/A”
Interventional model“Single Group Assignment”
Interventional model description“open-label, follow-up study”
Masking“None (Open Label)”
Phase“Phase 2”
Enrollment (actual)“22”
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants enrolled and analyzed in the posted results
MeasureQuoted record
Enrollment (actual)“22”
Overall number of baseline participants“22”
Overall number of participants analyzed, each outcome“22”
Description of analysis sets
Results
Participant disposition
Participant flow in the posted results
MilestoneABX464 50 mg
Started“22”
Completed“11”
Not completed“11”
Baseline characteristics
Demographics in the posted results
CharacteristicABX464 50 mg (N=22)
Age, years, mean (SD)“42.4(14.3)”
Female“9”
Male“13”
White“22”
Efficacy results
Month 48 outcomes with non-responder imputation in the posted results
Outcome (N=22)Quoted record
Participants with clinical response“11”
Participants with clinical remission“9”
Participants with endoscopic improvement“9”
Participants with endoscopic remission“6”
Change in total Mayo score, mean (SD)“-3.0(3.4)”
Change in partial Mayo score, mean (SD)“-2.2(2.4)”
Change in fecal calprotectin, µg/g, mean (SD)“-299.69(472.28)”
Change in CRP, mg/L, mean (SD)“2.29(4.82)”
Change in ESR, mm/hour, mean (SD)“2.90(8.62)”
Ulcerative colitis worsening reported as an adverse event (post hoc)
MeasureQuoted record
Overall number of participants analyzed“22”
Participants with UC worsening“7”
Health-related quality of life and patient-reported outcomes
SF-36 component scores at up to 24 months in the posted results
Outcome (N=22, non-responder imputation)Change from day 0, mean (SD)
SF-36 physical component“4.82(4.23)”
SF-36 mental component“6.38(3.40)”
Safety results
Adverse event counts in the posted results
Outcome (N=22)Events
Treatment-emergent adverse events“145”
Treatment-emergent serious adverse events“3”
Treatment-emergent adverse events of special interest“15”
Adverse events leading to investigational product discontinuation“1”
Specific laboratory abnormalities, first 12 months“17”
Deaths and serious adverse events in the posted results
MeasureAffected / at risk (%)
All-cause mortality“0/22 (0.00%)”
Serious adverse events, total“3/22 (13.64%)”
Myocardial infarction“1/22 (4.55%)”
Enteropathic spondylitis“1/22 (4.55%)”
Benign ovarian tumor“1/22 (4.55%)”
Other adverse events in at least 3 participants
EventAffected / at risk (%)
Other (not including serious) adverse events, total“20/22 (90.91%)”
Colitis ulcerative“7/22 (31.82%)”
Abdominal pain“5/22 (22.73%)”
Nasopharyngitis“5/22 (22.73%)”
Diarrhoea“4/22 (18.18%)”
Vomiting“3/22 (13.64%)”
Headache“3/22 (13.64%)”
Study limitations
Summary

ABX464-102 was a single-group, open-label extension without a control group, in which 22 participants who completed ABX464-101 (15 previously assigned to obefazimod and 7 to placebo) received obefazimod 50 mg once daily, at sites in Belgium, Hungary, and Poland (3, 9, and 10 participants). Enrollment was based on participant willingness and investigator judgement, and the protocol set no sample size beyond a “Maximum 30 subjects”. The planned treatment period was 12 months in a 2018 press release, 24 months after a data safety monitoring board recommendation reported in 2019, and 48 months in the 2022 protocol. The primary endpoint was the number of treatment-emergent adverse events; efficacy results were to be “presented descriptively”. Eleven of 22 participants completed the study. Interim efficacy was reported among participants with an endoscopy at each timepoint (12 of 16 in clinical remission at month 12, 11 of 16 at month 24, and 11 of 13 at month 36); endoscopies were read locally at month 12 and centrally at month 24. In the posted non-responder imputation analysis, 9 of 22 participants were in clinical remission at month 48. The statistical analysis plan defines clinical response by the modified Mayo score, and the posted outcome description defines it by the total Mayo score. Seven of 22 participants had ulcerative colitis worsening reported as an adverse event. SF-36 was assessed only to month 24, and the echocardiography endpoints were moved to a separate report that was not located. All 22 participants were White.